Adding the selective SGLT2 inhibitor dapagliflozin to intensive insulin therapy in adults with type 1 diabetes (T1D) who had sub-optimal glycemic control reduced blood glucose levels, aided in...

Canagliflozin does not increase the risk of amputation for the general type 2 diabetes (T2D) population or in patients with established cardiovascular disease, but does reduce a patient's risk of...

When patients with type 2 diabetes (T2D) receive intensified, multifactorial treatment combining lifestyle modification and pharmacological therapy for modifiable risk factors, there is no...

People with diabetes who have experienced recent acute coronary syndrome (ACS) and take a combination of alirocumab and statins may reduce their risk of future cardiac events by more than double...

Adults with type 1 diabetes (T1D) who take a daily dose of liraglutide demonstrated improvements in HbA1c levels, weekly average blood glucose levels and increased weight loss, according to the...